Firocoxib Safety and Efficacy Trial Completed in 429 Horses

  • Print
  • Email
  • Favorite
  • Share
  • Newsletters

In a recently completed 429-horse trial, researchers reinforced the effectiveness and safety profile of Equioxx (firocoxib), the first equine oral, nonsteroidal anti-inflammatory drug (NSAID) to be approved in more than 20 years.

"This research helps prove the benefits of Equioxx, and it also demonstrates the commitment to continued research for all Merial products," said Doug Carithers,

To continue reading this article, become a member of TheHorse.com.

It's FREE and you'll get full access to more than 20,000 articles, video, free reports & more.

Sign In
Stay on top of the most recent Horse Health news with FREE weekly newsletters from TheHorse.com. Learn More

Free Newsletters

Sign up for the latest in:

From our partners